Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 1, 2008, Pages 27-31

  Crespo, Manuel ^a   Caragol, Isabel ^a   Falcó, Vicenç ^a   Ribera, Esteban ^a   Urban, Susana ^a   Pahissa, Albert ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Discordant immune response; Recombinant IL 2

Indexed keywords

BIOLOGICAL MARKER; CD38 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 4; METHYLPREDNISOLONE; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEST TIGHTNESS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHRODERMA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; MALE; MULTIPLE CYCLE TREATMENT; OXYGEN THERAPY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 38549164056     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13114392     Document Type: Article

References (24)

1. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis. 2003;188:1794-803.
2. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS. 2003;17:343-51.
3. 3. J Infect Dis. 2000;181:1614-21.
4. Davey RT, Jr., Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA. 2000;284:183-9.
5. Arnó A, Ruiz L, Juan M, Jon A, Balagué M, Zayat MK, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤ 250/μL CD4 T cells and undetectable plasma virus load. J Infect Dis. 1999;180:56-60.
6. David D, Nait-Ighil L, Dupont B, Maral J, Gachot B, Theze J. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J Infect Dis. 2001;183:730-5.
7. Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis. 2002;186:606-16.
8. Katlama C, Carcelain G, Duvivier C, Chouguet C, Tubiana R, De Sa M, et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study - ANRS 082. AIDS. 2002;16:2027-34.
9. Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood. 2004;103:3282-6.
10. Renaud M, Katlama C, Mallet A, Calvez V, Carcelain G, Tubiana R, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS. 1999;13:669-76.
11. García F, de Lazzari LE, Plana M, Castro P, Mestre G, Nomdedeu M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;36:702-13.
12. Notermans DW, Pakker NG, Hamann D, Fondraine NA, Kauffmann RH, Meenhorst PL, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis. 1999;180:1050-6.
13. Kalayjian RC, Spritzler J, Pu M, Landay A, Pollard RB, Stocker V, et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis. 2005;192:1577-87.
14. Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pédron B, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis. 2005;191:1670-9.
15. Hansjee N, Kaufmann GR, Strub C, Weber R, Battegay M, Erb P. Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes. J Acquir Immune Defic Syndr. 2004;36:671-7.
16. Anthony KB, Yoder C, Metcalf JA, Der Simonian R, Orenstein JM, Stevens RA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr. 2003;33:125-33.
17. Hengge UR, Borchard C, Esser S, Schroder M, Mirmohammadsadegh A, Goos M. Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy. AIDS. 2002;16:151-60.
18. Pandolfi F, Pierdominici M, Marziali M, Liria Bernardi M, Antonelli G, Galati V, et al. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin Immunol. 2000;94:153-9.
19. Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, Metcalf JA, et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood. 2004;104:775-80.
20. De Paoli PP, Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C, et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest. 1997;100: 2737-43.
21. Almeida AR, Legrand N, Papiernik M, Freitas AA. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol. 2002;169:4850-60.
22. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005;174:4407-14.
23. Borthwick NJ, Bofill M, Gombert WM, Akbar AN, Medina E, Sagawa K, et al. Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28-T cells. AIDS. 1994;8:431-41.
24. Koletar SL, Williams PL, Wu J, McCutchan JA, Cohn SE, Murphy RL, et al. Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis. 2004;39:1500-6.